Publication
Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (13)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 13
- cancerInfantile Fibrosarcomacivic_curation1.00
- cancerSarcomacivic_curation1.00
- drugLarotrectinibcivic_curation1.00
- geneNTRK1civic_curation1.00
- geneNTRK2civic_curation1.00
- geneNTRK3civic_curation1.00
- variantNTRK1 Fusioncivic_curation1.00
- variantNTRK1 Fusioncivic_curation1.00
- variantNTRK1 Fusioncivic_curation1.00
- variantNTRK1 Fusioncivic_curation1.00
- variantNTRK1 Fusioncivic_curation1.00
- variantNTRK2 Fusioncivic_curation1.00
- variantNTRK3 Fusioncivic_curation1.00
Curated evidence
Evidence citing this paper (7)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 29606586
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| NTRK3 Fusion1 | ||||||||
| Larotrectinib | Infantile FibrosarcomaALIAS | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID6099Four out of six patients with infantile fibrosarcoma and a ETV6-NTRK3 fusion had a partial response, the remaining two had a complete response with larotrectinib. Treatment was done within a multicent… (full text at CIViC) PMID 29606586 · Laetsch et al., 2018 · Open in CIViC | civic |
| NTRK1 Fusion1 | ||||||||
| Larotrectinib | Infantile FibrosarcomaALIAS | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID6103One patient with infantile fibrosarcoma and a NTRK1-SQSTM1 fusion was treated with larotrectinib and exhibited a partial response. Treatment was done within a multicentre, open-label, phase 1/2 study … (full text at CIViC) PMID 29606586 · Laetsch et al., 2018 · Open in CIViC | civic |
| NTRK1 Fusion1 | ||||||||
| Larotrectinib | Sarcoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID6100One Patient with soft tissue sarcoma and a NTRK1-LMNA fusion had a partial response with larotrectinib. Treatment was done within a multicentre, open-label, phase 1/2 study and enrolled infants, child… (full text at CIViC) PMID 29606586 · Laetsch et al., 2018 · Open in CIViC | civic |
| NTRK1 Fusion1 | ||||||||
| Larotrectinib | Sarcoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID6102One Patient with soft tissue sarcoma and a NTRK1-PDE4DIP fusion was treated with larotrectinib and exhibited a partial response. Treatment was done within a multicentre, open-label, phase 1/2 study an… (full text at CIViC) PMID 29606586 · Laetsch et al., 2018 · Open in CIViC | civic |
| NTRK2 Fusion1 | ||||||||
| Larotrectinib | Sarcoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID6098One Patient with soft tissue sarcoma and a STRN-NTRK2 fusion had a partial Response with larotrectinib. Treatment was done within a multicentre, open-label, phase 1/2 study and enrolled infants, child… (full text at CIViC) PMID 29606586 · Laetsch et al., 2018 · Open in CIViC | civic |
| NTRK1 Fusion1 | ||||||||
| Larotrectinib | Sarcoma | Predictive | C | Supports Sensitivity Response | 4 | accepted | EID6101Four patients with infantile fibrosarcoma and soft tissue sarcoma and a TPM3::NTRK1 fusion were treated with larotrectinib. All four patients had a partial or complete response in the target lesion. T… (full text at CIViC) PMID 29606586 · Laetsch et al., 2018 · Open in CIViC | civic |
| NTRK1 Fusion1 | ||||||||
| Larotrectinib | Sarcoma | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID6569In a Phase 1/2 study involving 15 pediatric patients with infantile fibrosarcoma or soft tissue sarcoma, 8 patients had NTRK1 fusions. The patients were administered Larotrectinib, and 7 out of 8 pati… (full text at CIViC) PMID 29606586 · Laetsch et al., 2018 · Open in CIViC | civic |